Research ExplorerPublicationsThe JUPITER registry: One-year outcomes of transapical aorti...

The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation

Standard

The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. / Silaschi, Miriam; Conradi, Lenard; Wendler, Olaf; Schlingloff, Friederike; Kappert, Utz; Rastan, Ardawan J; Baumbach, Hardy; Holzhey, David; Eichinger, Walter; Bader, Ralf; Treede, Hendrik.

In: CATHETER CARDIO INTE, Vol. 91, No. 7, 06.2018, p. 1345-1351.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Silaschi, M, Conradi, L, Wendler, O, Schlingloff, F, Kappert, U, Rastan, AJ, Baumbach, H, Holzhey, D, Eichinger, W, Bader, R & Treede, H 2018, 'The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation', CATHETER CARDIO INTE, vol. 91, no. 7, pp. 1345-1351. https://doi.org/10.1002/ccd.27370

APA

Silaschi, M., Conradi, L., Wendler, O., Schlingloff, F., Kappert, U., Rastan, A. J., Baumbach, H., Holzhey, D., Eichinger, W., Bader, R., & Treede, H. (2018). The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. CATHETER CARDIO INTE, 91(7), 1345-1351. https://doi.org/10.1002/ccd.27370

Vancouver

Silaschi M, Conradi L, Wendler O, Schlingloff F, Kappert U, Rastan AJ et al. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. CATHETER CARDIO INTE. 2018 Jun;91(7):1345-1351. https://doi.org/10.1002/ccd.27370

Bibtex

@article{beda91b04b5d4ea799794e68bc237db4,
title = "The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation",
abstract = "OBJECTIVES: We present 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve used for aortic regurgitation (AR).BACKGROUND: Transcatheter aortic valve replacement (TAVR) is routine in high-risk patients with aortic stenosis but is not recommended for AR. The JenaValve{\texttrademark} (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism.METHODS: The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012-2015, 30 patients with AR were enrolled.RESULTS: Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One-year Kaplan-Meier survival was 79.9%, one-year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow-up.CONCLUSIONS: The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One-year results using the JenaValve for AR encourage its use for this indication.",
keywords = "Aged, Aged, 80 and over, Aortic Valve/diagnostic imaging, Aortic Valve Insufficiency/diagnostic imaging, Female, Heart Valve Prosthesis, Humans, Male, Product Surveillance, Postmarketing, Prospective Studies, Prosthesis Design, Recovery of Function, Registries, Risk Assessment, Risk Factors, Time Factors, Transcatheter Aortic Valve Replacement/adverse effects, Treatment Outcome",
author = "Miriam Silaschi and Lenard Conradi and Olaf Wendler and Friederike Schlingloff and Utz Kappert and Rastan, {Ardawan J} and Hardy Baumbach and David Holzhey and Walter Eichinger and Ralf Bader and Hendrik Treede",
note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2018",
month = jun,
doi = "10.1002/ccd.27370",
language = "English",
volume = "91",
pages = "1345--1351",
journal = "CATHETER CARDIO INTE",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation

AU - Silaschi, Miriam

AU - Conradi, Lenard

AU - Wendler, Olaf

AU - Schlingloff, Friederike

AU - Kappert, Utz

AU - Rastan, Ardawan J

AU - Baumbach, Hardy

AU - Holzhey, David

AU - Eichinger, Walter

AU - Bader, Ralf

AU - Treede, Hendrik

N1 - © 2017 Wiley Periodicals, Inc.

PY - 2018/6

Y1 - 2018/6

N2 - OBJECTIVES: We present 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve used for aortic regurgitation (AR).BACKGROUND: Transcatheter aortic valve replacement (TAVR) is routine in high-risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism.METHODS: The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012-2015, 30 patients with AR were enrolled.RESULTS: Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One-year Kaplan-Meier survival was 79.9%, one-year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow-up.CONCLUSIONS: The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One-year results using the JenaValve for AR encourage its use for this indication.

AB - OBJECTIVES: We present 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve used for aortic regurgitation (AR).BACKGROUND: Transcatheter aortic valve replacement (TAVR) is routine in high-risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism.METHODS: The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012-2015, 30 patients with AR were enrolled.RESULTS: Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One-year Kaplan-Meier survival was 79.9%, one-year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow-up.CONCLUSIONS: The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One-year results using the JenaValve for AR encourage its use for this indication.

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve/diagnostic imaging

KW - Aortic Valve Insufficiency/diagnostic imaging

KW - Female

KW - Heart Valve Prosthesis

KW - Humans

KW - Male

KW - Product Surveillance, Postmarketing

KW - Prospective Studies

KW - Prosthesis Design

KW - Recovery of Function

KW - Registries

KW - Risk Assessment

KW - Risk Factors

KW - Time Factors

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Treatment Outcome

U2 - 10.1002/ccd.27370

DO - 10.1002/ccd.27370

M3 - SCORING: Journal article

C2 - 29171730

VL - 91

SP - 1345

EP - 1351

JO - CATHETER CARDIO INTE

JF - CATHETER CARDIO INTE

SN - 1522-1946

IS - 7

ER -